Clinical Trial Update: Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars in Subjects Undergoing Elective Abdominoplasty [Phase 2]

View source ↗

Summary

Phase 2 trial assessing EXC 001 for improving scar appearance after elective abdominoplasty has completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scar Prevention

Drugs mentioned

• EXC 001

Snippet

Sponsor: Pfizer | Conditions: Scar Prevention | Phase 2 | Status: COMPLETED | Results posted: 2021-08-02